Biomm S.A. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was BRL 104.95 million compared to BRL 107.09 million a year ago. Net loss was BRL 92.56 million compared to BRL 80.26 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.77 BRL | +10.99% | +8.62% | +207.44% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
1st Jan change | Capi. | |
---|---|---|
+207.44% | 310M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.39% | 22.18B | |
-16.67% | 21.2B | |
-9.12% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- BIOM3 Stock
- News Biomm S.A.
- Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022